This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Neoplasms  • Nevi  • Liver/ Biliary Tract/ Pancreatic Diseases  • Immunologic Disorders  • Alert me on articles by topic

Adina Figl, MD; Ranjit K. Thirumaran, PhD; Selma Ugurel, MD; Andreas Gast, PhD; Kari Hemminki, MD; Rajiv Kumar, PhD; Dirk Schadendorf, MD

Arch Dermatol. 2007;143(4):495-499.

Background  A 19–base pair germline deletion in exon 2 of the CDKN2A (cyclin-dependent kinase inhibitor 2A) gene (Leiden mutation) has been detected in Dutch families with familial melanomas. The penetrance of CDKN2A mutations varies widely and is influenced by environmental and unrelated genetic factors such as variants in the MC1R gene.

Observations  We describe a 25-year-old German woman who developed 8 invasive melanomas and 6 in situ melanomas after radiation therapy and polychemotherapy for Hodgkin lymphoma. Genetic testing revealed a constitutional CDKN2A Leiden mutation in the proband and her sister, mother, and mother's sister. The proband also carried high-risk MC1R variant alleles R151C and R160W, which she had inherited from her father and her mother, respectively. The less affected mutation carrier sister did not have high-risk MC1R variant alleles. Analysis of DNA from paraffin-embedded tissues showed loss of heterozygosity at CDKN2A loci in all 3 melanomas studied but not in Hodgkin lymphoma. The pedigree revealed several types of cancers on both sides of the family, but no Dutch ancestors were found. No mutations in the CDK4, B-raf, and N-ras genes were detected either in the germline or in tumors from the patient.

Conclusion  This study shows the variability of the penetrance of the CDKN2A Leiden mutation within the same family, which could be due to genetic or exogenous factors.

Author Affiliations: Skin Cancer Unit (Drs Figl, Ugurel, and Schadendorf) and Division of Molecular Genetic Epidemiology (Drs Thirumaran, Gast, Hemminki, and Kumar), German Cancer Research Center, Heidelberg, Germany; Department of Dermatology, University Hospital of Mannheim, Mannheim, Germany (Drs Figl, Ugurel, and Schadendorf); and Department of Biosciences, Karolinska Institute, Huddinge, Sweden (Drs Hemminki and Kumar).

RELATED ARTICLES

Store-and-Forward Teledermatology in Skin Cancer Triage: Experience and Evaluation of 2009 Teleconsultations
David Moreno-Ramirez, Lara Ferrandiz, Adoracion Nieto-Garcia, Rafael Carrasco, Pedro Moreno-Alvarez, Rafael Galdeano, Esther Bidegain, Juan J. Rios-Martin, and Francisco M. Camacho
Arch Dermatol. 2007;143(4):479-483.
ABSTRACT | FULL TEXT  

Melanoma Outcomes for Medicare Patients: Association of Stage and Survival With Detection by a Dermatologist vs a Nondermatologist
Michelle L. Pennie, Seaver L. Soon, Jessica B. Risser, Emir Veledar, Steven D. Culler, and Suephy C. Chen
Arch Dermatol. 2007;143(4):488-494.
ABSTRACT | FULL TEXT  

Phenotypic Variation in Familial Melanoma: Consequences for Predictive DNA Testing
Wilma Bergman and Nelleke A. Gruis
Arch Dermatol. 2007;143(4):525-526.
EXTRACT | FULL TEXT  

Melanoma of the Foot and Ankle: A Case Series of an Underrecognized Entity
Hubert T. Greenway, Jr, Joy M. Twersky, Shanna B. Meads, and Benjamin F. Kelley
Arch Dermatol. 2007;143(4):543-544.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Phenotypic Variation in Familial Melanoma: Consequences for Predictive DNA Testing
Bergman and Gruis
Arch Dermatol 2007;143:525-526.
FULL TEXT